Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.

Athena M Soulika1, M Claire H Holland, Georgia Sfyroera

  • 1Protein Chemistry Laboratory, Department of Pathology and Laboratory Medicine, 402 Stellar Chance, 422 Curie Blvd., University of Pennsylvania, Philadelphia, PA 19104, United States.

Molecular Immunology
|February 14, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement C3 deficiency increases the effector and cytotoxic functions of NK cells and suppresses tumor growth.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Towards adaptive bioelectronic wound therapy with integrated real-time diagnostics and machine learning-driven closed-loop control.

npj biomedical innovations·2026
Same author

A multi therapy bioelectronic wound dressing.

npj biomedical innovations·2026
Same author

A Flow Cytometry Workflow for Identifying Myeloid Subsets in Porcine Wound Tissue.

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society·2026
Same author

Characterization of cutaneous wound healing in swine.

JID innovations : skin science from molecules to population health·2026
Same author

Adherence to adjuvant endocrine therapy in breast cancer: a single regional Australian centre experience.

Frontiers in oncology·2026

Compstatin, a complement inhibitor, binds to a specific 40-kDa region on complement factor 3 (C3). This finding advances understanding of complement regulation and potential drug design for complement-mediated diseases.

Area of Science:

  • Immunology
  • Biochemistry
  • Drug Discovery

Background:

  • Compstatin is a peptidic inhibitor of the complement system, specifically targeting complement factor 3 (C3) cleavage.
  • Unlike other regulators, Compstatin binds both native and activated C3, acting via a mechanism independent of C3 convertase destabilization or C3b degradation.

Purpose of the Study:

  • To identify the specific binding site of Compstatin on complement factor 3 (C3).
  • To elucidate the structural requirements for Compstatin-C3 interaction for future complement-based drug design.

Main Methods:

  • Synthesis of a photo-crosslinking Compstatin analog to probe C3 interaction sites.
  • Identification of the Compstatin binding region using crosslinking and binding assays with recombinant C3 fragments.

Related Experiment Videos

Main Results:

  • A 40-kDa region at the C-terminus of the C3 beta-chain was identified as the Compstatin binding site.
  • Binding specificity was confirmed through inhibition studies with Compstatin and inactive analogs.
  • Proper protein conformation within larger fragments, not smaller peptides, is necessary for Compstatin binding.

Conclusions:

  • The C3 beta-chain's C-terminal 40-kDa region is crucial for Compstatin binding.
  • This newly identified binding site, not previously linked to C3 cleavage, offers novel avenues for complement regulation research.
  • Findings support the development of complement-based therapeutics targeting C3.